Business
GE HealthCare announces Flyrcado milestone: Strong pilot results drive broader rollout at CVAUSA
CVAUSA, the largest network of private cardiology groups in the U.S., plans to broadly adopt Flyrcado in line with its mission to deliver the highest quality
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nCVAUSA, the largest network of private cardiology groups in the U.S., plans to broadly adopt Flyrcado in line with its mission to deliver the highest quality cardiovascular care for patients.\n\n\n\nCVAUSA currently performs approximately 85,000 cardiac positron emission tomography (PET) procedures annually, highlighting the potential opportunity for Flyrcado as adoption grows.\n\n\n\nGE HealthCare remains committed to driving innovation and collaborating with leading cardiology groups to advance PET myocardial perfusion imaging (MPI) technology.\n\n\n\n ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today announced that Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado™ (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117055825/en/Woman looking at a cardiac PET scan\nThe pilot at Cardiovascular Medicine provided cardiologists with an opportunity to evaluate Flyrcado in real-world workflows. “The pilot demonstrated that Flyrcado can be seamlessly integrated into a high-volume cardiac PET practice,” said Dr. Edmund Coyne, former President of Cardiovascular Medicine. “In our Davenport location, we routinely perform 12+ cardiac PET scans a day, and during our two-week, 21 patient pilot, we found that Flyrcado fits smoothly into that workflow without disruption. We saw firsthand the benefits in diagnostic confidence and efficiency, as well as excellent image quality, and we look forward to seeing these advantages scaled across CVAUSA’s network.”\n\n\n“Our mission is to deliver the highest quality cardiovascular care, and expanding the use of advanced cardiac PET imaging is a key part of that,” said Tim Attebery, Chief Executive Officer of CVAUSA. “We perform approximately 85,000 cardiac PET procedu...